

Supplemental Digital Content 2. Univariate analysis of risk factors associated with anal SCC in HIV-positive subjects.

Univariate Models	IRR (95%CI)	<i>p</i>
HBV past or current	4.92 (2.09, 11.63)	<0.001
HCV past or current ^a	1.20 (0.54, 2.69)	0.653
Age group: 30-49	Reference	
50-59	6.07 (3.14, 11.73)	<0.001
60-70	6.19 (2.50, 15.35)	<0.001
Race: Non-African American	Reference	
African American	1.13 (0.53, 2.42)	0.757
No. of sexual partners ^b : ≤2/6 months	Reference	
>2/6 months	1.02 (0.53, 1.98)	0.949
Tobacco use ^c : <0.5 pack/day	Reference	
≥0.5 pack/day	1.40 (0.73, 2.66)	0.308
Poppers use: <1 year daily or weekly use	Reference	
≥1 year daily or weekly use	0.74 (0.38, 1.44)	0.381
No HAART use at endpoint	0.25 (0.09, 0.71)	0.009
CD4+ count ≥500 cells/μl	Reference	
<500 cells/μl lagged 1 year	1.75 (0.94, 3.25)	0.077
<500 cells/μl lagged 6 years	2.38 (1.26, 4.47)	0.007
CD4+ nadir ≥350 cells/μl	Reference	
<350 cells/μl	2.39 (0.94, 6.06)	0.066
CD4:CD8 ratio ≥0.5	Reference	
<0.5 lagged 1 year	1.50 (0.83, 2.7)	0.178
<0.5 lagged 6 years	2.85 (1.55, 5.24)	<0.001
CD4:CD8 nadir ≥0.5	Reference	
<0.5	2.70 (0.84, 8.7)	0.097

Poisson regression models: *p* values calculated using Wald's test, bold indicates *p* < 0.05.

All HIV-positive subjects are included (n = 2725).

CI, confidence interval; HAART, highly active anti-retroviral therapy; HBV, hepatitis B virus;

HCV, hepatitis C virus; IRR, incidence rate ratio.

^a Positive tests for HCV antibodies or HCV RNA any time prior to endpoint compared with subjects with negative tests, restricted to subjects with available test data (n = 2653).

^b Average over first three visits.

^c Average over 10 years prior to endpoint.